ATE540680T1 - Pharmazeutische aripiprazol-zusammensetzungen - Google Patents

Pharmazeutische aripiprazol-zusammensetzungen

Info

Publication number
ATE540680T1
ATE540680T1 AT07823939T AT07823939T ATE540680T1 AT E540680 T1 ATE540680 T1 AT E540680T1 AT 07823939 T AT07823939 T AT 07823939T AT 07823939 T AT07823939 T AT 07823939T AT E540680 T1 ATE540680 T1 AT E540680T1
Authority
AT
Austria
Prior art keywords
aripiprazole
pharmaceutical compositions
aripiprazole pharmaceutical
compositions
exhibit
Prior art date
Application number
AT07823939T
Other languages
English (en)
Inventor
Ian Wilding
Russell Pendleton
Original Assignee
Zysis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37421592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE540680(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zysis Ltd filed Critical Zysis Ltd
Application granted granted Critical
Publication of ATE540680T1 publication Critical patent/ATE540680T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
AT07823939T 2006-09-26 2007-09-26 Pharmazeutische aripiprazol-zusammensetzungen ATE540680T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0618879.1A GB0618879D0 (en) 2006-09-26 2006-09-26 Pharmaceutical compositions
PCT/GB2007/003677 WO2008038003A2 (en) 2006-09-26 2007-09-26 Pharmaceutical compositions of aripiprazole

Publications (1)

Publication Number Publication Date
ATE540680T1 true ATE540680T1 (de) 2012-01-15

Family

ID=37421592

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07823939T ATE540680T1 (de) 2006-09-26 2007-09-26 Pharmazeutische aripiprazol-zusammensetzungen

Country Status (13)

Country Link
US (2) US8575172B2 (de)
EP (1) EP2066325B1 (de)
JP (1) JP2010504950A (de)
KR (1) KR20090065514A (de)
AT (1) ATE540680T1 (de)
AU (1) AU2007301742B2 (de)
CA (1) CA2664455A1 (de)
DK (1) DK2066325T3 (de)
ES (1) ES2395119T3 (de)
GB (1) GB0618879D0 (de)
IL (1) IL197574A (de)
PT (1) PT2066325E (de)
WO (1) WO2008038003A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0618879D0 (en) * 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
MY156288A (en) 2008-07-16 2016-01-29 Richter Gedeon Nyrt Pharmaceutical formulations containing dopamine receptor ligands.
US8372808B2 (en) * 2008-10-31 2013-02-12 Wisconsin Alumni Research Foundation Suppression of glial fibrillary acidic protein
JP5664871B2 (ja) * 2009-06-19 2015-02-04 株式会社 メドレックス アリピプラゾールと有機酸を有効成分とする外用剤組成物
CN102670553A (zh) * 2011-03-14 2012-09-19 北京天衡药物研究院 盐酸文拉法辛渗透泵控释片
WO2012129232A1 (en) * 2011-03-21 2012-09-27 Conour James Compositions for the treatment of psychotic or neurological disorders
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
WO2013175508A2 (en) 2012-05-24 2013-11-28 Medreich Limited Stable pharmaceutical composition of aripiprazole
WO2014144426A1 (en) * 2013-03-15 2014-09-18 Ameritox, Ltd. Methods of monitoring for adherence to aripiprazole therapy
CN103393594A (zh) * 2013-08-22 2013-11-20 万特制药(海南)有限公司 一种新的阿立哌唑的制剂组合物
US10525057B2 (en) * 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
CN103536594A (zh) * 2013-10-21 2014-01-29 江苏亚虹医药科技有限公司 G蛋白偶联受体拮抗剂在用于制备治疗谷氨酸受体高表达肿瘤药物中的用途
US20190070174A1 (en) * 2016-03-10 2019-03-07 The Regents Of The University Of Michigan Methods of treating neurodegenerative diseases
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
HUP1700253A1 (hu) 2017-06-13 2019-01-28 Richter Gedeon Nyrt Szilárd orális gyógyszerkészítmények
MX2020005517A (es) 2017-12-05 2020-11-09 Sunovion Pharmaceuticals Inc Formas cristalinas y metodos de produccion de las mismas.
US10369134B2 (en) 2017-12-05 2019-08-06 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
CN110025572A (zh) * 2018-01-11 2019-07-19 四川科伦药物研究院有限公司 月桂酰阿立哌唑混悬剂及其制备方法
EP3789029B1 (de) * 2018-05-04 2024-05-08 Korea Institute of Radiological & Medical Sciences Zusammensetzung zur erhöhung der strahlungsempfindlichkeit mit aripiprazol als wirkstoff
EP3861028A1 (de) * 2018-10-04 2021-08-11 École Polytechnique Fédérale de Lausanne (EPFL) Vernetzbares polymer, hydrogel und verfahren zu seiner herstellung
EP3870292A4 (de) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York Kombination von serotonin-spezifischem wiederaufnahmeinhibitor und serotonin-1a-rezeptor-partialagonist zur verminderung von l-dopa-induzierter dyskinesie
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
WO2020247627A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
WO2022146462A1 (en) * 2020-12-31 2022-07-07 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
KR102525213B1 (ko) 2021-01-13 2023-04-25 아주대학교산학협력단 Qr 코드가 적용된 구강붕해필름 및 3d 프린팅 기술을 이용한 이의 제조방법

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
GB9611328D0 (en) 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
EP1353675A2 (de) 2001-01-02 2003-10-22 PHARMACIA & UPJOHN COMPANY Neue kombination von norepinehrin reuptake hemmern und neuroleptika
MY129350A (en) 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
EA009780B1 (ru) 2001-06-19 2008-04-28 Норберт Мюллер Применение ингибиторов cox-2 для лечения шизофрении, аффективных расстройств или осложнений, связанных с тиком
SE0102887D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
CA2475839A1 (en) 2002-02-08 2003-08-14 Abbott Laboratories Combination therapy for treatment of schizophrenia
US20060073516A1 (en) * 2002-03-28 2006-04-06 Yasuaki Ito Novel screening method
DE10224170A1 (de) * 2002-05-31 2003-12-11 Desitin Arzneimittel Gmbh Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
JP2005538108A (ja) 2002-07-29 2005-12-15 ポトマック， ファーマ， エルエルシー α−２アドレナリン作動性レセプターアンタゴニストと非定型抗精神病薬精神安定薬との抗精神病薬組み合わせ治療および組成物
EP1551393A4 (de) 2002-07-30 2010-06-16 Peter Migaly Kombinationstherapie gegen depression, prävention von suizid und verschiedener medizinischer und psychiatrischer erkrankungen
GEP20063996B (en) 2002-08-20 2006-12-11 Bristol Myers Squibb Co Aripiprazole complex formulation and use thereof
WO2004039320A2 (en) 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. STEREOISOMERS OF p-HYDROXY-MILNACIPRAN, AND METHODS OF USE THEREOF
EP1606262A1 (de) 2003-03-21 2005-12-21 Hetero Drugs Limited Neue kristalline formen von aripiprazol
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
WO2005048979A2 (en) 2003-10-06 2005-06-02 Torrent Pharmaceuticals Limited Pharmaceutical composition having casing with multiple micro tablets
EP1689367A1 (de) * 2003-10-21 2006-08-16 Actavis Group HF Pharmazeutische formulierungen mit quetiapin
KR100931784B1 (ko) * 2003-10-23 2009-12-14 오츠카 세이야쿠 가부시키가이샤 방출조절성 멸균 아리피프라졸 주사제, 그 제조방법
DE10353196A1 (de) * 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix
EP2272514A1 (de) 2003-12-02 2011-01-12 PharmaNeuroBoost N.V. Verwendung von niedrigdosiertem Pipamperon und einem zweiten Wirkstoff zur Behandlung von neurodegenerativen Erkrankungen
US7504504B2 (en) 2003-12-16 2009-03-17 Teva Pharmaceutical Industries Ltd. Methods of preparing aripiprazole crystalline forms
JP2007519705A (ja) 2004-01-29 2007-07-19 ファイザー・プロダクツ・インク Ｃｎｓ障害を治療するための非定型抗精神病薬とアミノメチルピリジルオキシメチル／ベンゾイソオキサゾールアザビシクロ誘導体の組合せ
MXPA06012059A (es) * 2004-04-22 2007-01-25 Boehringer Ingelheim Int Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii.
MXPA06013163A (es) 2004-05-11 2007-02-13 Pfizer Prod Inc Combinacion de antipsicoticos atipicos y antagonistas del receptor 5-ht1b.
TWI338583B (en) 2004-05-20 2011-03-11 Otsuka Pharma Co Ltd Solid pharmaceutical formulation
WO2006000222A2 (en) 2004-06-24 2006-01-05 H. Lundbeck A/S The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia
WO2006012237A2 (en) 2004-06-25 2006-02-02 Shanghai Institute Of Pharmaceutical Industry Aripiprazole crystaline forms and associated methods
GB0417702D0 (en) 2004-08-09 2004-09-08 Merck Sharp & Dohme New uses
CN101087760B (zh) 2004-11-18 2011-09-28 斯索恩有限公司 结晶的阿立哌唑溶剂化物
AU2005319367B2 (en) 2004-12-20 2012-05-24 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
WO2006096439A2 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
ES2526415T3 (es) 2005-03-17 2015-01-12 Synthon B.V. Comprimidos farmacéuticos de aripiprazol cristalino de tipo II
WO2007004061A1 (en) 2005-04-15 2007-01-11 Medichem, S.A. Syntheses and preparations of polymorphs of crystalline aripiprazole
HUP0500683A3 (en) 2005-07-14 2009-03-30 Egis Gyogyszergyar Nyilvanosan New arylpiprazole salts for producing pharmaceutical composition
EP1933814A2 (de) 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoteilchenförmige aripiprazol-formulierungen
CN101351193A (zh) 2006-01-05 2009-01-21 特瓦制药工业有限公司 阿立哌唑的干法制剂
DE602006004694D1 (de) 2006-01-05 2009-02-26 Teva Pharma Feuchtgranulierungsmethode zur Herstellung pharmazeutischer Aripiprazolzusammensetzungen
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
GB0618879D0 (en) 2006-11-01
JP2010504950A (ja) 2010-02-18
AU2007301742A1 (en) 2008-04-03
KR20090065514A (ko) 2009-06-22
US8575172B2 (en) 2013-11-05
EP2066325A2 (de) 2009-06-10
PT2066325E (pt) 2012-04-13
EP2066325B1 (de) 2012-01-11
IL197574A0 (en) 2009-12-24
DK2066325T3 (da) 2012-04-30
US20140044786A1 (en) 2014-02-13
ES2395119T3 (es) 2013-02-08
US20100004262A1 (en) 2010-01-07
AU2007301742B2 (en) 2013-05-02
WO2008038003A3 (en) 2008-06-26
WO2008038003A2 (en) 2008-04-03
CA2664455A1 (en) 2008-04-03
IL197574A (en) 2012-07-31

Similar Documents

Publication Publication Date Title
ATE540680T1 (de) Pharmazeutische aripiprazol-zusammensetzungen
LT2046298T (lt) Farmacinė vaisto forma, turinti farmaciniu požiūriu priimtiną soliubilizuojančią kompoziciją
CL2007002967A1 (es) Forma cristalina a del compuesto 4-[3-(4-ciclopropancarbonil-piperazin-1-carbonil)-4-fluoro-bencil]-2h-ftalazin-1-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un
IL199152A (en) Annals 2 - (piperidine-4-ram) -4-phenoxy or phenylamino-pyrimidine, containing and containing pharmaceutical preparations for the preparation of viral infections
IL228017A0 (en) Quinazolinone derivatives donated at position 5 as anti-cancer agents
EA200900264A1 (ru) Композиции флибансерина и способ их приготовления
EP1824442A4 (de) Pharmazeutische und therapeutische zusammensetzungen aus der garcinia-mangostana-l-pflanze
WO2007027527A3 (en) Isoindole-imide compounds and compositions comprising and methods of using the same
BRPI1009392A2 (pt) "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
BRPI0816255A2 (pt) Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
MX2010007083A (es) Combinacion anti-retroviral.
BRPI0814666A2 (pt) composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
ZA200605631B (en) Directly compressible pharmaceutical composition for the oral administration of CCI-779
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
ZA200805761B (en) Pharmaceutical composition for the treatment of nail disease
ATE479427T1 (de) Pharmazeutische zusammensetzung mit candesartan- cilexetil
CY1114306T1 (el) Νεα συνθεση για τη θεραπευτικη αντιμετωπιση της ιδιοπαθους θρομβοκυτταραιμιας
WO2008004100A9 (en) Therapeutic compounds
WO2010079433A3 (en) Pharmaceutical composition comprising melogliptin
TR201803451T4 (tr) Olmesartan formülasyonlari.
WO2011039675A3 (en) Latrepirdine transdermal therapeutic dosage forms
JO3239B1 (ar) تركيبات جالينية من مركبات عضوية
EA200901387A1 (ru) Фармацевтическая композиция, включающая дезлоратадин
MX2008010233A (es) Composicion de liberacion modificada, que comprende doxofilina.